The invention discloses an application of a
fusion gene RPL17-C18orf32 as a benzo [g, h, i]
perylene acute
exposure marker, an in-vitro benzo [g, h, i]
perylene acute
exposure human lung bronchial epithelial cell model is established,
abnormal expression of the
fusion gene RPL17-C18orf32 is detected, and RPL17-C18orf32 participates in benzo [g, h, i]
perylene acute
exposure marker expression. The processes of
cell proliferation capacity decline,
apoptosis rate increase, cycle disorder,
cell DNA damage and the like caused by acute exposure of benzo [g, h, i] perylene, so that the
fusion gene RPL17-C18orf32 can be used as a biomarker for acute exposure of benzo [g, h, i] perylene. The invention not only provides a
potential biomarker for early diagnosis for evaluating the acute exposure of the benzo [g, h, i] perylene, but also provides a new strategy for developing diseases related to the acute exposure of the benzo [g, h, i] perylene for preventing and treating the acute exposure of the benzo [g, h, i] perylene.